Orasure Technologies Inc (OSUR) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Orasure Technologies Inc  (NASDAQ: OSUR)

Select the Financial Report: Select the Period:


Description of Orasure Technologies Inc's Business Segments


Orasure Technologies Inc. is a prominent provider of innovative solutions in the fields of infectious disease testing and genomics. The company operates across two primary segments: Infectious Disease Testing Products and Molecular Collection and Genomics Products. Each segment offers a comprehensive portfolio of products and services designed to enhance diagnostic capabilities and support clinical research.

Segments

1. Infectious Disease Testing Products
- This segment focuses on rapid diagnostic testing for various infectious diseases, primarily targeting viruses that significantly impact public health, such as HIV, Hepatitis C and B, and Zika virus. The segment also emphasizes the importance of sample collection and stabilization, providing laboratory instruments and supplies that enable effective testing in clinical environments.

2. Molecular Collection and Genomics Products
- The molecular segment is dedicated to collecting and analyzing genetic material, offering products and services for DNA and RNA collection, gene expression analysis, and genotyping. This segment also includes services aimed at supporting genetic testing, thereby contributing to advancements in personalized medicine and clinical research.

Products and Services

Infectious Disease Testing Products

1. OraQuick HIV-1/2
- A rapid, easy-to-use test that detects antibodies for HIV-1 and HIV-2. Results are available in just 20 minutes, significantly improving access to timely testing. The test is offered in two formats:
- Oral fluid, which is easy to use and non-invasive, and
- Fingerstick blood, which allows for traditional blood-based testing.

2. OraQuick HCV
- This rapid test detects antibodies to Hepatitis C virus (HCV) and delivers results in 20 minutes. Similar to the HIV test, it is available in oral fluid and fingerstick blood formats, allowing for flexible implementation in various testing environments.

3. OraSure Oral Specimen Collection Device
- This device is specifically designed to collect and stabilize oral fluid specimens for a range of infectious diseases, including HIV and Hepatitis B and C. The device enables efficient transportation of samples while preserving the integrity of the collected specimens.

4. Intercepte Blood System for Pathogens
- Utilizing advanced proprietary technology, this system is designed to inactivate a wide array of pathogens in donated blood and blood components. Its primary objective is to enhance blood safety by significantly reducing the risk of transfusion-transmitted infections.

Molecular Collection and Genomics Products

1. Genoteke DNA/RNA Collection Devices
- This product facilitates the collection, stabilization, and concentration of DNA and RNA from diverse sample types, including saliva, urine, and blood. The devices ensure that genetic material is preserved for subsequent analysis, essential for research and clinical purposes.

2. QIAGEN Reagents
- Orasure offers an array of reagents and consumables specifically formulated for genomic analysis. This includes products for genomic DNA and RNA isolation and purification, PCR amplification, and gene expression analysis, providing comprehensive solutions for genetic research.

3. Microarray Analysis
- The company provides a service that encompasses the analysis of genetic variations and gene expression profiles using state-of-the-art microarray technology. This service is vital for researchers looking to identify genomic differences related to diseases and other conditions.

4. Support for Genetic Testing
- An integral part of this segment, Orasure offers comprehensive services to support genetic testing initiatives. This includes training, consulting, and clinical trial support, ensuring that healthcare providers and researchers can effectively implement genetic testing in their practices.

Summary
Orasure Technologies Inc. delivers an extensive range of innovative products and services aimed at improving the quality and accessibility of infectious disease diagnostics and genomic analysis. With a focus on rapid testing, effective sample collection, and meticulous genomic research support, Orasure remains a key player in advancing healthcare technologies for better patient outcomes. Their products are strategically developed for use in clinical settings, research laboratories, and various healthcare facilities, ensuring they meet the evolving needs of the healthcare community.


Composition of Orasure Technologies Inc Revenues by Segments

 
Product and Services    183.1 % of total Revenue
Other Non-product and services revenues    8.04 % of total Revenue
HIV    88.74 % of total Revenue
United States    126.99 % of total Revenue
HCV    19.77 % of total Revenue
Other Product and Services Revenues    12.74 % of total Revenue
Product and Services Revenues COVID-19    0.06 % of total Revenue
Africa    44.26 % of total Revenue
Product and Services Revenues HCV    9.48 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Product and Services 56.10 183.1 %
Other Non-product and services revenues 2.46 8.04 %
HIV 27.19 88.74 %
United States 38.91 126.99 %
HCV 6.06 19.77 %
Other Product and Services Revenues 3.90 12.74 %
Product and Services Revenues COVID-19 0.02 0.06 %
Africa 13.56 44.26 %
Product and Services Revenues HCV 2.91 9.48 %
Total 30.64 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Product and Services - 112.69 %
Other Non-product and services revenues - 59.07 %
HIV - -
United States - 108.37 %
HCV - -
Other Product and Services Revenues - -
Product and Services Revenues COVID-19 - 5.56 %
Africa - 100.18 %
Product and Services Revenues HCV - 9.09 %
Total - 10.2 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 6.25 20.4 %




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Orasure Technologies Inc Divisions, Sales by Country

 
Product and Services   Product and Services Segment contribution to total sales 95.5 % of total Revenue
Other Non-product and services revenues   Other Non-product and services revenues Segment contribution to total sales 5.22 % of total Revenue
United States   United States Segment contribution to total sales 68.52 % of total Revenue
Product and Services Revenues COVID-19   Product and Services Revenues COVID-19 Segment contribution to total sales 12.05 % of total Revenue
Africa   Africa Segment contribution to total sales 21.01 % of total Revenue
Product and Services Revenues HCV   Product and Services Revenues HCV Segment contribution to total sales 4.07 % of total Revenue
Product and Services Revenues HIV   Product and Services Revenues HIV Segment contribution to total sales 43.61 % of total Revenue
Product and Services Revenues Sample Management Solutions   Product and Services Revenues Sample Management Solutions Segment contribution to total sales 33.59 % of total Revenue
Product and Services Revenues Other Product And Services   Product and Services Revenues Other Product And Services Segment contribution to total sales 0.55 % of total Revenue
Europe   Europe Segment contribution to total sales 6.47 % of total Revenue
Other regions   Other regions Segment contribution to total sales 4.71 % of total Revenue
Product and Services Revenues Risk Assessment Testing   Product and Services Revenues Risk Assessment Testing Segment contribution to total sales 1.63 % of total Revenue
Other   Other Segment contribution to total sales 100.72 % of total Revenue


Twelve months ended 2025
OSUR s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Product and Services 109.06 95.5 %
Other Non-product and services revenues 5.97 5.22 %
United States 78.25 68.52 %
Product and Services Revenues COVID-19 13.76 12.05 %
Africa 23.99 21.01 %
Product and Services Revenues HCV 4.65 4.07 %
Total 114.20 100 %
Product and Services Revenues HIV 49.80 43.61 %
Product and Services Revenues Sample Management Solutions 38.36 33.59 %
Product and Services Revenues Other Product And Services 0.62 0.55 %
Europe 7.39 6.47 %
Other regions 5.38 4.71 %
Product and Services Revenues Risk Assessment Testing 1.87 1.63 %
Other 115.02 100.72 %


Twelve months ended 2025
OSUR s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -68.73 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Product and Services -40.93 % -
Other Non-product and services revenues 390.63 % -
United States -43.77 % -
Product and Services Revenues COVID-19 -1.89 % -
Africa -26.73 % -
Product and Services Revenues HCV 32.57 % -
Total -38.4 % -
Product and Services Revenues HIV -18.09 % -
Product and Services Revenues Sample Management Solutions -24.86 % -
Product and Services Revenues Other Product And Services -98.62 % -
Europe -12.24 % -
Other regions -2.07 % -
Product and Services Revenues Risk Assessment Testing -77.66 % -
Other -38.1 % -
Product and Services Revenues Molecular Services - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.